Real-world treatment patterns and overall survival in <i>BRAF</i>-mutant melanoma patients treated with immunotherapy or targeted therapy-Reference-Cited by-同舟云学术

Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

Published:2022-06 Issue:18 Volume:18 Page:2233-2245
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Atkins Michael B¹^ORCID,Julian Cristina²^ORCID,Secrest Matthew H²^ORCID,Lee Janet²,Abajo-Guijarro Ana M³,McKenna Edward²

Affiliation:

1. Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA

2. Genentech, Inc, South San Francisco, CA 94080, USA

3. F Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract

Aim: To assess overall survival (OS) in patients with advanced BRAF-mutant melanoma by first-line (1L) targeted therapy (TT) or checkpoint inhibitor (CPI) use, second-line (2L) TT or CPI use, and treatment sequence. Patients & methods: Advanced BRAF-mutant melanoma patients treated with 1L CPI or TT were selected from a real-world, electronic health record-derived database. Results: CPI was associated with improved survival after adjustment for potential confounders (hazard ratio, 0.75 [95% CI, 0.66–0.87]). Median OS was similar between 2L therapies and among likely treatment sequences. Conclusion: This real-world study demonstrated a survival benefit with 1L CPI versus TT. Analyses of 2L and treatment sequences were unable to detect or rule out clinically relevant differences in OS.

Funder

F Hoffmann-La Roche

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-1536

Reference31 articles.

1. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

2. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

3. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

4. BRAF targeted therapy changes the treatment paradigm in melanoma

5. Systemic Therapy for Melanoma: ASCO Guideline

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study);Cancer Medicine;2023-08-16

2. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial;The Lancet;2023-07

3. Real‐world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy;Pharmacoepidemiology and Drug Safety;2023-04-24

4. Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients;Melanoma Research;2022-10-15